Article
作者: Vasquez, Yasmin M ; Palmer, Stephen S ; Wang, Jian ; Chen, Ruihong ; Jimmidi, Ravikumar ; Ku, Angela F ; Ta, Hai Minh ; Sharma, Kiran L ; Young, Damian W ; Bohren, Kurt M ; Yu, Zhifeng ; Kim, Choel ; Sankaran, Banumathi ; Sutton, Courtney M ; Qin, Xuan ; Kent, Katarzyna ; Robers, Matthew B ; Matzuk, Martin M ; Teng, Mingxing ; Wang, Yong ; Wilkinson, Jennifer ; Tan, Zhi ; Li, Feng ; Madasu, Chandrashekhar ; Ye, Qiuji ; Li, Jian-Yuan ; Hakenjos, John M ; Chamakuri, Srinivas ; Palaniappan, Murugesan ; Ma, Lang
Men or mice with homozygous serine/threonine kinase 33 (
STK33
) mutations are sterile owing to defective sperm morphology and motility. To chemically evaluate STK33 for male contraception with STK33-specific inhibitors, we screened our multibillion-compound collection of DNA-encoded chemical libraries, uncovered potent STK33-specific inhibitors, determined the STK33 kinase domain structure bound with a truncated hit CDD-2211, and generated an optimized hit CDD-2807 that demonstrates nanomolar cellular potency (half-maximal inhibitory concentration = 9.2 nanomolar) and favorable metabolic stability. In mice, CDD-2807 exhibited no toxicity, efficiently crossed the blood-testis barrier, did not accumulate in brain, and induced a reversible contraceptive effect that phenocopied genetic
STK33
perturbations without altering testis size. Thus, STK33 is a chemically validated, nonhormonal contraceptive target, and CDD-2807 is an effective tool compound.